Isomorphic Labs announces a cross-modality, multi-target research collaboration with Johnson & Johnson. This partnership brings together Iso’s AI-first approach to drug discovery with Johnson & Johnson’s expertise in drug discovery and development.
Isomorphic Labs’ foundational drug design engine is capable of generating drug candidates against challenging targets across a range of modalities such as small molecules, antibodies, peptides and molecular glues. This collaboration will leverage this multi-modality discovery capability, including large molecule and biologics design.
Read more in the news release below.
